Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

New effective strategies are required that specifically address the challenges of multiple
myeloma (MM) treatment, namely, disease recurrence, immunosuppression, and treatment …

Background: Multiple myeloma (MM) is a hematological cancer caused by a proliferation of
clonal plasma cells, leading to anemia, renal failure, hypercalcemia and destructive bone …

Immunomodulatory drugs (IMiDs) are thalidomide analogues, which possess pleiotropic anti-
myeloma properties including immune-modulation, anti-angiogenic, anti-inflammatory and …

Immunomodulatory derivatives of thalidomide (IMiD compounds), such as pomalidomide
and lenalidomide, are highly active in multiple myeloma (MM) treatment. However, the …

Although outcomes for patients with multiple myeloma (MM) have improved over the past
decade, the disease remains incurable and even patients who respond well to induction …

Although several mechanisms have been proposed to explain the activity of thalidomide,
lenalidomide and pomalidomide in multiple myeloma (MM), including demonstrable anti …

Multiple myeloma (MM) is a clonal plasma cell malignancy clinically characterized by
osteolytic lesions, immunodeficiency, and renal disease. There are an estimated 750,000 …

Multiple myeloma is a B-cell malignancy characterized by an excess of monotypic plasma
cells in the bone marrow. The molecular mechanisms that are involved in disease …

Multiple Myeloma (MM) is an incurable malignancy with current treatment choices primarily
comprising combination regimens implemented with a risk-adapted approach. Cereblon …